Roland Y. Leung

102 Pokfulam Road
Hong Kong, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Anti-Tumor Immunity in Solid-Organ Transplant Recipients.

Anti-Tumor Immunity in Solid-Organ Transplant Recipients.

Journal: Cancers

Published: January 31, 2026

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.

Journal: Hong Kong medical journal = Xianggang yi xue za zhi

Published: December 04, 2025

A survey of respiratory physicians on investigating and managing tuberculous pleuritis.

A survey of respiratory physicians on investigating and managing tuberculous pleuritis.

Journal: Scientific reports

Published: December 01, 2025

Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma.

Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma.

Journal: Biomedicines

Published: September 21, 2025

A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.

A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.

Journal: Investigational new drugs

Published: August 25, 2025

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer.

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer.

Journal: ESMO open

Published: July 23, 2025

Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis.

Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Liver cancer

Published: May 23, 2025

A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial.

A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial.

Journal: Translational gastroenterology and hepatology

Published: January 14, 2025

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: October 30, 2024

Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.

Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.

Journal: Oncology and therapy

Published: January 25, 2024

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?

Journal: Hepatology communications

Published: January 30, 2023

Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.

Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.

Journal: Advances in therapy

Published: August 24, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026